Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with poor prognosis, and understanding the molecular mechanisms underlying its progression is crucial for developing ...
Head and neck squamous cell carcinoma (HNSCC) remains a globally prevalent malignancy with high morbidity and mortality. Despite therapeutic advances, patient outcomes are hindered by tumor ...
Invasive lung squamous cell carcinoma (LUSC) accounts for approximately one-quarter of all lung cancers, but therapeutic options for LUSC remain limited, primarily due to the absence of well-defined, ...
Morning Overview on MSN
A bispecific antibody beat a standard immunotherapy regimen head-to-head in squamous lung cancer at ASCO 2026
A bispecific antibody that simultaneously targets PD-1 and VEGF extended overall survival by more than four months compared with a standard PD-1 inhibitor when each was combined with chemotherapy in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results